{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:33:07Z","timestamp":1771475587484,"version":"3.50.1"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hyperglycemia is an important pathogenic component in the development of microvascular and macrovascular complications in type 2 diabetes mellitus. Inhibition of renal tubular glucose reabsorption that leads to glycosuria has been proposed as a new mechanism to attain normoglycemia and thus prevent and diminish these complications. Sodium glucose cotransporter 2 (SGLT2) has a key role in reabsorption of glucose in kidney. Competitive inhibitors of SGLT2 have been discovered and a few of them have also been advanced in clinical trials for the treatment of diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To discuss the therapeutic potential of SGLT2 inhibitors currently in clinical development.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>A number of preclinical and clinical studies of SGLT2 inhibitors have demonstrated a good safety profile and beneficial effects in lowering plasma glucose levels, diminishing glucotoxicity, improving glycemic control and reducing weight in diabetes. Of all the SGLT2 inhibitors, dapagliflozin is a relatively advanced compound with regards to clinical development.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>SGLT2 inhibitors are emerging as a promising therapeutic option for the treatment of diabetes. Their unique mechanism of action offers them the potential to be used in combination with other oral anti-diabetic drugs as well as with insulin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.2042-7158.2012.01574.x","type":"journal-article","created":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T10:15:17Z","timestamp":1344507317000},"page":"317-327","source":"Crossref","is-referenced-by-count":26,"title":["SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus"],"prefix":"10.1093","volume":"65","author":[{"given":"Monika","family":"Misra","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Jawaharlal Nehru Medical College, Aligarh Muslim University , Uttar Pradesh,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,3,1]]},"reference":[{"key":"2024103109160304100_cit1","first-page":"3","article-title":"Large and micro coronary vascular involvement in diabetes","volume":"57","author":"L'Abbate","year":"2005","journal-title":"Pharmacol Rep"},{"key":"2024103109160304100_cit2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1515\/JPEM.2003.16.1.5","article-title":"Glucotoxicity and beta-cell failure in type 2 diabetes mellitus","volume":"16","author":"Kaiser","year":"2003","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2024103109160304100_cit3","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J Clin Invest"},{"key":"2024103109160304100_cit4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.287.3.360","article-title":"Oral antihyperglycemic therapy for type 2 diabetes: scientific review","volume":"287","author":"Inzucchi","year":"2002","journal-title":"JAMA"},{"key":"2024103109160304100_cit5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1079\/BJN2002763","article-title":"Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins","volume":"89","author":"Wood","year":"2003","journal-title":"Br J Nutr"},{"key":"2024103109160304100_cit6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00424-003-1085-0","article-title":"The SLC2 family of facilitated hexose and polyol transporters","volume":"447","author":"Uldry","year":"2004","journal-title":"Pflugers Arch"},{"key":"2024103109160304100_cit7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1210\/jc.2009-0473","article-title":"Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus","volume":"95","author":"Nair","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2024103109160304100_cit8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00424-003-1202-0","article-title":"The sodium\/glucose cotransport family SLC5","volume":"447","author":"Wright","year":"2004","journal-title":"Pflugers Arch"},{"key":"2024103109160304100_cit9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J Clin Invest"},{"key":"2024103109160304100_cit10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition \u2013 a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2024103109160304100_cit11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ng0296-216","article-title":"Defects in Na+\/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactosemalabsorption","volume":"12","author":"Mart\u00edn","year":"1996","journal-title":"Nat Genet"},{"key":"2024103109160304100_cit12","doi-asserted-by":"crossref","first-page":"15204","DOI":"10.1016\/S0021-9258(17)36592-4","article-title":"Structure of the human Na+\/glucose cotransporter gene SGLT1","volume":"269","author":"Turk","year":"1994","journal-title":"J Biol Chem"},{"key":"2024103109160304100_cit13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.112.193045","article-title":"KGA-2727, a novel selective inhibitor of high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models","volume":"342","author":"Shibazaki","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103109160304100_cit14","volume-title":"A 2-Part trial in subjects with type 2 diabetes and in healthy subjects to evaluate GSK1614235, a new glucose lowering drug to treat type 2 diabetes (SGA112534)","year":"2011"},{"issue":"1A","key":"2024103109160304100_cit15","first-page":"LB5","article-title":"LX4211, a dual SGLT2\/SGLT1 inhibitor, shows rapid and significant improvement in glycemic control over 28 days in patients with type 2 diabetes","volume":"59","author":"Freiman","year":"2010","journal-title":"Diabetes"},{"key":"2024103109160304100_cit16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11892-012-0275-6","article-title":"Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"12","author":"Abdul-Ghani","year":"2012","journal-title":"Curr Diab Rep"},{"key":"2024103109160304100_cit17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00439-002-0820-5","article-title":"Autosomal recessive renal glycosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)","volume":"111","author":"van den Heuvel","year":"2002","journal-title":"Hum Genet"},{"key":"2024103109160304100_cit18","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","article-title":"Molecular analysis of the SGLT2 gene in patients with renal glycosuria","volume":"14","author":"Santer","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2024103109160304100_cit19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/0026-0495(71)90017-5","article-title":"Autosomal recessive inheritance of renal glycosuria","volume":"20","author":"Elsas","year":"1971","journal-title":"Metabolism"},{"key":"2024103109160304100_cit20","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1172\/JCI106150","article-title":"Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine","volume":"48","author":"Elsas","year":"1969","journal-title":"J Clin Invest"},{"key":"2024103109160304100_cit21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00439-003-1054-x","article-title":"Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glycosuria","volume":"114","author":"Calado","year":"2004","journal-title":"Hum Genet"},{"key":"2024103109160304100_cit22","first-page":"156","article-title":"Complete absence of tubular glucose reabsorption: a new type of renal glycosuria (type 0)","volume":"27","author":"Oemar","year":"1987","journal-title":"Clin Nephrol"},{"issue":"2","key":"2024103109160304100_cit23","first-page":"F283","article-title":"Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats","volume":"266","author":"Dominguez","year":"1994","journal-title":"Am J Physiol"},{"key":"2024103109160304100_cit24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","article-title":"Na (+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity","volume":"149","author":"Freitas","year":"2008","journal-title":"Endocrinology"},{"key":"2024103109160304100_cit25","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"2024103109160304100_cit26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2008.01829.x","article-title":"Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes","volume":"62","author":"Jabbour","year":"2008","journal-title":"Int J Clin Pract"},{"key":"2024103109160304100_cit27","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"2024103109160304100_cit28","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1734-1140(09)70133-1","article-title":"Inhibitors of type 2 sodium glucose co-transporters \u2013 a new strategy for diabetes treatment","volume":"61","author":"Boldys","year":"2009","journal-title":"Pharmacol Rep"},{"key":"2024103109160304100_cit29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI115031","article-title":"Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression","volume":"87","author":"Kahn","year":"1991","journal-title":"J Clin Invest"},{"key":"2024103109160304100_cit30","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"2024103109160304100_cit31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4155\/cli.10.12","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: a review of phase II and III trials","volume":"1","author":"Kipnes","year":"2010","journal-title":"Clin. Invest"},{"key":"2024103109160304100_cit32","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2024103109160304100_cit33","first-page":"A21","article-title":"Dapagliflozin in patients with type 2 diabetes poorly controlled on insulin therapy \u2013 efficacy of a novel insulin-independent treatment","volume":"59","author":"Wilding","year":"2010","journal-title":"Diabetes"},{"key":"2024103109160304100_cit34","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled non-inferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"2024103109160304100_cit35","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozinmonotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"2024103109160304100_cit36","author":"Bristol Myers Squibb company (research and development)","year":"2011"},{"key":"2024103109160304100_cit37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3810\/pgm.2011.05.2291","article-title":"Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment","volume":"123","author":"Meyers","year":"2011","journal-title":"Postgrad Med"},{"key":"2024103109160304100_cit38","author":"FDAAdvisory Committee Meeting","year":"2011"},{"key":"2024103109160304100_cit39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"key":"2024103109160304100_cit40","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"2024103109160304100_cit41","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","article-title":"T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes","volume":"48","author":"Oku","year":"1999","journal-title":"Diabetes"},{"issue":"120","key":"2024103109160304100_cit42","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/ki.2010.511","article-title":"SGLT2 inhibitors: molecular design and potential differences in effect","volume":"79","author":"Isaji","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"2024103109160304100_cit43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1177\/0091270009351879","article-title":"Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus","volume":"50","author":"Hussey","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2024103109160304100_cit44","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/0091270009352185","article-title":"Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozinetabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study","volume":"50","author":"Hussey","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2024103109160304100_cit45","volume-title":"Remogliflozin etabonate, a selective inhibitor of the sodium\u2013glucose transporter 2 (SGLT2) reduces serum glucose in type 2 diabetes mellitus (T2DM) patients","author":"Dobbins"},{"key":"2024103109160304100_cit46","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J Med Chem"},{"key":"2024103109160304100_cit47","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"2024103109160304100_cit48","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"2024103109160304100_cit49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"1A","key":"2024103109160304100_cit50","first-page":"LB12","article-title":"Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"2024103109160304100_cit51","volume-title":"FDA advisory committee meeting","author":"Irony","year":"2011"},{"key":"2024103109160304100_cit52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrd3546","article-title":"Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor","volume":"10","author":"Jones","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2024103109160304100_cit53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.560181","article-title":"A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials","volume":"44","author":"Musso","year":"2012","journal-title":"Ann Med"},{"key":"2024103109160304100_cit54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.arcmed.2004.09.003","article-title":"Renal handling of uric acid in patients with type 1 diabetes in relation to glycemic control","volume":"36","author":"Golembiewska","year":"2005","journal-title":"Arch Med Res"},{"key":"2024103109160304100_cit55","volume-title":"Diabetes Drug Dapagliflozin Rejected by FDA","author":"Pollack","year":"2011"},{"key":"2024103109160304100_cit56","volume-title":"FDA Delays Approval of New Diabetes Drug","author":"Pollack","year":"2012"},{"key":"2024103109160304100_cit57","volume-title":"European Medicines Agency","author":"Forxiga","year":"2012)"},{"key":"2024103109160304100_cit58","volume-title":"Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes","author":"Johnson & Johnson","year":"2012"},{"key":"2024103109160304100_cit59","volume-title":"R & D Pipeline","author":"Boehringer Ingelheim","year":"2012"},{"key":"2024103109160304100_cit60","volume-title":"R& D pipeline","author":"Astella Pharma Inc","year":"2012"},{"key":"2024103109160304100_cit61","volume-title":"Drug pipeline","author":"Lexicon Pharmaceuticals","year":"2012"},{"key":"2024103109160304100_cit62","volume-title":"New drug pipeline.","author":"Taisho Pharmaceuticals Co. Ltd","year":"2012"},{"key":"2024103109160304100_cit63","volume-title":"Development pipeline","author":"Chugai pharmaceuticals Co. Ltd","year":"2012"},{"key":"2024103109160304100_cit64","volume-title":"Pipeline","author":"Pfizer","year":"2012"},{"key":"2024103109160304100_cit65","volume-title":"Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes","author":"ClinicalTrial.gov","year":"2011"},{"key":"2024103109160304100_cit66","volume-title":"Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers","author":"ClinicalTrials.gov","year":"2009"},{"key":"2024103109160304100_cit67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2024103109160304100_cit68","volume-title":"Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin","author":"Rosenstock"},{"key":"2024103109160304100_cit69","first-page":"A274","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM)","volume":"60","author":"Inagaki","year":"2011","journal-title":"Diabetes"},{"key":"2024103109160304100_cit70","first-page":"A271","article-title":"Efficacy and safety of BI 10773, a new sodium glucose cotransporter-2 (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin","volume":"60","author":"Rosenstock","year":"2011","journal-title":"Diabetes"},{"key":"2024103109160304100_cit71","first-page":"S351","article-title":"The potent and highly selective sodium glucose co transporter-2 (SGLT2) inhibitor BI 10773 is safe and efficacious monotherapy in patients with type 2 diabetes mellitus","volume":"53","author":"Ferrannini","year":"2010","journal-title":"Diabetologia"},{"key":"2024103109160304100_cit72","volume-title":"ASP1941, a novel, selective SGLT2 Inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus","author":"Kashiwagi"},{"key":"2024103109160304100_cit73","first-page":"S68","article-title":"Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study","volume":"54","author":"Kashiwagi","year":"2011","journal-title":"Diabetologia"},{"key":"2024103109160304100_cit74","first-page":"A274","article-title":"TS-071, a novel and selective SGLT2 inhibitor, improved glycemic control and decreased body weight in 12-week study of Japanese patients with type 2 diabetes mellitus","volume":"60","author":"Seino","year":"2011","journal-title":"Diabetes"},{"key":"2024103109160304100_cit75","first-page":"S347","article-title":"The sodium glucose co-transported PF04971729 provides multifaced improvement in diabetic patients inadequately controlled on metformin","volume":"54","author":"Nucci","year":"2011","journal-title":"Diabetologia"},{"key":"2024103109160304100_cit76","volume-title":"Long term safety and efficacy of ISIS 388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species","author":"Wancewicz"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.2012.01574.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/65\/3\/317\/60252344\/j.2042-7158.2012.01574.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/65\/3\/317\/60252344\/j.2042-7158.2012.01574.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:22:31Z","timestamp":1730366551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/65\/3\/317\/6132966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,1]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,1]]},"published-print":{"date-parts":[[2013,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.2012.01574.x","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,3]]},"published":{"date-parts":[[2013,3,1]]}}}